Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?
Jingmei Hsu(Cancer Research Institute), Koen van Besien(University Hospitals of Cleveland), Michael S. Samuel(Cancer Research UK Scotland Institute), Usama Gergis(Thomas Jefferson University Hospital), Tsiporah B. Shore(Cornell University), Pinkal Desai(NewYork–Presbyterian Hospital), Ellen K. Ritchie(Cornell University), Yassine Tahri(Université Libre de Bruxelles), Sang‐Min Lee(Seoul National University), Zhengming Chen(Cornell University), Gail J. Roboz(Cornell University), Sebastian Mayer(Mount Sinai Hospital), Adrienne A. Phillips(Palmetto Hematology Oncology)
Cited by 3
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k